Clinical lymphadenopathy (cN+) from prostate cancer (PCa) identified on imaging remains a contraindication to radical prostatectomy (RP) according to guidelines. We tested the hypothesis that there would be no difference in survival between patients with and without cN+ on preoperative imaging who underwent RP and pelvic lymph node dissection with detection of pelvic lymph node metastasis (LNM).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
A total of 302 patients with LNM were retrospectively reviewed (1988-2003) and stratified according to cN status on the basis of preoperative imaging. Univariable and multivariable Cox regression analyses were performed to evaluate cN+ as a predictor of survival. Of the 302 patients, 50 (17%) had cN+; the 252 (83%) patients with negative preoperative imaging comprised the cN0 group. During median follow-up of 17.4 yr, 161 deaths were recorded, 70 of which were from PCa. Among the entire LNM cohort, the number of positive lymph nodes (hazard ratio [HR] 1.10; p=0.02) and pathologic Gleason score 8-10 versus ≤6 (HR 2.37; p=0.04) were significant predictors of cancer-specific mortality (CSM). cN+ was not a significant predictor of CSM (p=0.6). Selected patients with cN+ have similar clinical outcomes to those with normal preoperative imaging in the setting of LNM.
Clinical lymph node metastases are not a factor in determining survival after radical prostatectomy and pelvic lymph node dissection in patients with prostate cancer. Thus, the presence of clinical lymph node metastases should not be considered as an absolute contraindication to treatment with curative intent.
Eur Urol. 2015 Aug 8. pii: S0302-2838(15)00706-X. doi: 10.1016/j.eururo.2015.07.047. [Epub ahead of print]
Moschini M1, Briganti A2, Murphy CR3, Bianchi M2, Gandaglia G2, Montorsi F2, Quevedo JF4, Carlson R5, Kwon E3, Karnes RJ6.
1 Department of Urology, Mayo Clinic, Rochester, MN, USA; Unit of Urology/Division of Oncology; IRCCS Ospedale San Raffaele; URI Milan, Italy.
2 Unit of Urology/Division of Oncology; IRCCS Ospedale San Raffaele; URI Milan, Italy.
3 Department of Urology, Mayo Clinic, Rochester, MN, USA.
4 Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
5 Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
6 Department of Urology, Mayo Clinic, Rochester, MN, USA.